Entrar Registro gratuito

Last updated: 24 June 2024 at 4:06pm EST

Michael Carter Net Worth




The estimated Net Worth of Michael G Carter is at least $299 mil dollars as of 1 September 2020. Michael Carter owns over 71,429 units of Oncternal Therapeutics stock worth over $298,940 and over the last 19 years he sold ONCT stock worth over $0. In addition, he makes $0 as Independent Director at Oncternal Therapeutics.

Michael Carter ONCT stock SEC Form 4 insiders trading

Michael has made over 1 trades of the Oncternal Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 71,429 units of ONCT stock worth $150,001 on 1 September 2020.

The largest trade he's ever made was buying 71,429 units of Oncternal Therapeutics stock on 1 September 2020 worth over $150,001. On average, Michael trades about 1,880 units every 0 days since 2006. As of 1 September 2020 he still owns at least 71,947 units of Oncternal Therapeutics stock.

You can see the complete history of Michael Carter stock trades at the bottom of the page.





Michael Carter biography

Dr. Michael G. Carter serves as Independent Director of the Company.D. serves as Independent Director of the Company. Previously, Dr. Carter was a non-executive director of Santarus, Inc. from 2004 to 2013, served as a non-executive director of Micromet AG from 2001 to 2005 and of MICROMET, Inc. from 2006 to March 2012, and served as a non-executive director of Fulcrum Pharma, PLC from 2005 to 2010. Dr. Carter was a member of the Advisory Board of Paul Capital Royalty Fund from 2005 to 2008, and was a venture partner with SV Life Sciences Advisors, LLP from 1998 to 2016. He has served as a member of the strategic advisory board of Healthcare Royalty Partners (HCRP) since September 2009 and a member of the HCRP Investment Committee since 2015. Dr. Carter was the non-executive chairman of Metris Therapeutics, Ltd., a biotechnology firm specializing in women's healthcare from 1999 to 2008. He was also a non-executive director of ONCOETHIX from June 2013 until its sale to Merck & Co., in December 2014. Dr. Carter served on the Pharmaceutical Board of I.C.I. Zeneca Pharmaceuticals, a predecessor company of AstraZeneca, and held various positions with I.C.I. Zeneca from 1984 to 1998, including International Medical Director and International Marketing Director. From 1985 to 1995, Dr. Carter served as a member of the U.K. Government's Medicines Commission. Dr. Carter is an Elected Fellow of the Royal Pharmaceutical Society, Faculty of Pharmaceutical Medicine, and of the Royal College of Physicians of Edinburgh. Dr. Carter holds a degree in pharmacy from London University (U.K.) and a medical degree from Sheffield University Medical School (U.K.). The board of directors believes that Dr. Carter’s specific expertise in the development and commercialization of pharmaceutical products by both large pharmaceutical companies and small specialty biotech companies provide him with the qualifications and expertise to serve as a director of the Company.



How old is Michael Carter?

Michael Carter is 82, he's been the Independent Director of Oncternal Therapeutics since 2006. There are no older and 15 younger executives at Oncternal Therapeutics.

What's Michael Carter's mailing address?

Michael's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 230, , SAN DIEGO, CA, 92130.

Insiders trading at Oncternal Therapeutics

Over the last 5 years, insiders at Oncternal Therapeutics have traded over $26,287 worth of Oncternal Therapeutics stock and bought 1,526,610 units worth $3,062,129 . The most active insiders traders include Pharmaceutical (Usa) Inc.Sh..., Charles Theuer, eRobert James Wills. On average, Oncternal Therapeutics executives and independent directors trade stock every 68 days with the average trade being worth of $302,970. The most recent stock trade was executed by Robert James Wills on 8 April 2024, trading 3,086 units of ONCT stock currently worth $27,651.



What does Oncternal Therapeutics do?

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1. The company is headquartered in San Diego, California.



What does Oncternal Therapeutics's logo look like?

Oncternal Therapeutics, Inc. logo

Complete history of Michael Carter stock trades at Oncternal Therapeutics

Data
#
Companhia
 Acionista maioritário
Trans.
Transação
 Ações Preço por ação Preço total Ações após Fonte
1 Sep 2020 ONCT Oncternal Therapeutics, Inc. Michael G Carter
Comprar 71,429 $2.10 $150,001
1 Sep 2020
71,947 ↗


Oncternal Therapeutics executives and stock owners

Oncternal Therapeutics executives and other stock owners filed with the SEC include: